BRPI0922233A2 - compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. - Google Patents

compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.

Info

Publication number: BRPI0922233A2
Authority: BR; Brazil
Prior art keywords: compounds; treatment; methods; pharmaceutical compositions; metabolic syndromes
Prior art date: 2008-12-08

Application number

BRPI0922233A

Other languages

English (en)

Inventor

Evangelos Brantis Cyrille

Schils Didier

Dutheuil Guillaume

Hoveyda Hamid

Bernard Jérôme

Zoute Ludivine

Original Assignee

Euroscreen Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-08

Filing date

2009-12-07

Publication date

2018-05-29

2009-12-07 Application filed by Euroscreen Sa filed Critical Euroscreen Sa

2018-05-29 Publication of BRPI0922233A2 publication Critical patent/BRPI0922233A2/pt

Links

208000001145 Metabolic Syndrome Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0922233A 2008-12-08 2009-12-07 compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. BRPI0922233A2 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP08305896		2008-12-08
US20573509P	2009-01-23	2009-01-23
US15229409P	2009-02-13	2009-02-13
US16815909P	2009-04-09	2009-04-09
PCT/EP2009/066536 WO2010066682A1 (en)	2008-12-08	2009-12-07	Compounds, pharmaceutical composition and methods for use in treating metabolic disorders

Publications (1)

Publication Number	Publication Date
BRPI0922233A2 true BRPI0922233A2 (pt)	2018-05-29

Family

ID=40602401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922233A BRPI0922233A2 (pt)	2008-12-08	2009-12-07	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.

Country Status (14)

Country	Link
US (1)	US20110230477A1 (pt)
EP (1)	EP2364297A1 (pt)
JP (1)	JP2012510979A (pt)
KR (1)	KR20110097930A (pt)
CN (1)	CN102245574A (pt)
AU (1)	AU2009326108A1 (pt)
BR (1)	BRPI0922233A2 (pt)
CA (1)	CA2745843A1 (pt)
CR (1)	CR20110318A (pt)
EA (1)	EA201100921A1 (pt)
EC (1)	ECSP11011082A (pt)
IL (1)	IL212707A0 (pt)
MX (1)	MX2011006006A (pt)
WO (1)	WO2010066682A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011021678A1 (ja) *	2009-08-21	2011-02-24	武田薬品工業株式会社	縮合複素環化合物
WO2011076732A1 (en) *	2009-12-21	2011-06-30	Euroscreen S.A.	Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
WO2011076734A1 (en) *	2009-12-21	2011-06-30	Euroscreen S.A.	Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2011151434A1 (en)	2010-06-04	2011-12-08	Euroscreen S.A.	Novel compounds, pharmaceutical composition and methods for use in treating metabolic disorders
WO2012147916A1 (ja)	2011-04-28	2012-11-01	日本たばこ産業株式会社	アミド化合物およびその医薬用途
JP6215315B2 (ja) *	2012-06-12	2017-10-18	アッヴィ・インコーポレイテッド	ピリジノンおよびピリダジノン誘導体
GB2513403A (en) *	2013-04-26	2014-10-29	Agency Science Tech & Res	WNT pathway modulators
KR101730958B1 (ko)	2013-12-16	2017-04-27	삼성에스디아이 주식회사	리튬 이차 전지용 전해질 및 이를 포함하는 리튬 이차 전지
KR101656662B1 (ko) *	2014-11-18	2016-09-12	한국생명공학연구원	2-옥소-1,2,3,4-테트라하이드로피리미딘-5-카르복사미드 유도체를 유효성분으로 함유하는 대사성 질환 예방 또는 치료용 약학적 조성물
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh)	2018-02-13	2020-10-21	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
JP7053010B2 (ja) *	2018-03-05	2022-04-12	公立大学法人大阪	ジアリールエテン化合物、フォトクロミック材料、及び調光部材
KR102591947B1 (ko)	2018-04-19	2023-10-25	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
EP3820572B1 (en)	2018-07-13	2023-08-16	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
US12030875B2 (en)	2018-09-07	2024-07-09	PIC Therapeutics, Inc.	EIF4E inhibitors and uses thereof
US11236085B2 (en)	2018-10-24	2022-02-01	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
AU2021230289A1 (en)	2020-03-03	2022-09-29	PIC Therapeutics, Inc.	eIF4E inhibitors and uses thereof
JP2024534127A (ja)	2021-08-25	2024-09-18	ピクセラピューティクス，インコーポレイテッド	ｅＩＦ４Ｅ阻害剤及びその使用
US12157732B2 (en)	2021-08-25	2024-12-03	PIC Therapeutics, Inc.	eIF4E inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6534513B1 (en) *	1999-09-29	2003-03-18	Celltech R&D Limited	Phenylalkanoic acid derivatives
AU2003233780A1 (en) *	2002-06-27	2004-01-19	Novo Nordisk A/S	Novel glucagon antagonists/inverse agonists
WO2004072066A1 (en) *	2003-02-11	2004-08-26	Prosidion Limited	Tri(cyclo) substituted amide glucokinase activator compounds
US20050143384A1 (en) *	2003-10-30	2005-06-30	Eric Sartori	Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
CA2563192A1 (en) *	2004-04-21	2005-11-03	Prosidion Limited	Tri(cyclo) substituted amide compounds
CA2619153C (en) *	2005-01-21	2013-12-31	President And Fellows Of Harvard College	Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
DE102006021874B4 (de) *	2006-05-11	2008-03-27	Sanofi-Aventis	4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

2009
- 2009-12-07 CN CN2009801501527A patent/CN102245574A/zh active Pending
- 2009-12-07 CA CA2745843A patent/CA2745843A1/en not_active Abandoned
- 2009-12-07 BR BRPI0922233A patent/BRPI0922233A2/pt not_active IP Right Cessation
- 2009-12-07 KR KR1020117015683A patent/KR20110097930A/ko not_active Withdrawn
- 2009-12-07 US US13/130,567 patent/US20110230477A1/en not_active Abandoned
- 2009-12-07 JP JP2011539049A patent/JP2012510979A/ja active Pending
- 2009-12-07 EA EA201100921A patent/EA201100921A1/ru unknown
- 2009-12-07 WO PCT/EP2009/066536 patent/WO2010066682A1/en not_active Ceased
- 2009-12-07 EP EP09765103A patent/EP2364297A1/en not_active Withdrawn
- 2009-12-07 AU AU2009326108A patent/AU2009326108A1/en not_active Abandoned
- 2009-12-07 MX MX2011006006A patent/MX2011006006A/es not_active Application Discontinuation
2011
- 2011-05-05 IL IL212707A patent/IL212707A0/en unknown
- 2011-05-25 EC EC2011011082A patent/ECSP11011082A/es unknown
- 2011-06-08 CR CR20110318A patent/CR20110318A/es unknown

Also Published As

Publication number	Publication date
IL212707A0 (en)	2011-07-31
WO2010066682A1 (en)	2010-06-17
KR20110097930A (ko)	2011-08-31
JP2012510979A (ja)	2012-05-17
ECSP11011082A (es)	2011-09-30
CR20110318A (es)	2011-09-09
EA201100921A1 (ru)	2011-12-30
WO2010066682A4 (en)	2010-08-26
MX2011006006A (es)	2011-09-08
US20110230477A1 (en)	2011-09-22
AU2009326108A1 (en)	2010-06-17
CN102245574A (zh)	2011-11-16
CA2745843A1 (en)	2010-06-17
EP2364297A1 (en)	2011-09-14

Legal Events

Date	Code	Title	Description
2018-06-05	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-10-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
LTC2340031I2 (lt)	2022-06-27	Gdf gaudyklės, skirtos naudoti anemijos gydymui
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0910503A2 (pt)	2015-09-29	compostos, composições farmacêuticas e respectivos usos.
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0906962A2 (pt)	2015-07-14	Composto, e, composição farmacêutica
BRPI0906556A2 (pt)	2015-07-07	Composto, e, composição farmacêutica
BRPI0718688A2 (pt)	2013-12-24	Composições de baixa irritação e métodos para preparar as mesmas.
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BR112012022879A2 (pt)	2016-06-14	composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0822104A2 (pt)	2014-10-07	Composições antimicrobianas e métodos para o uso das mesmas
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0918652A2 (pt)	2015-08-25	Composições farmacêuticas e métodos de libração relacionadas.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0917681A2 (pt)	2015-08-04	Composto, e, composição farmacêutica
CL2008000403A1 (es)	2008-08-18	Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
BR112012031226A2 (pt)	2018-03-06	composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0807078A2 (pt)	2014-04-08	Composto, e, formulação farmacêutica
BRPI0911612A2 (pt)	2015-12-15	composições e métodos para o tratamento da esclerose múltipla.
DK2254873T3 (da)	2014-06-30	Benzodiazepinforbindelse og farmaceutisk sammensætning.
BRPI0909818A2 (pt)	2015-10-06	métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos